Clinical Trials Logo
  1. Home
  2. Cutaneous T-Cell Lymphoma
  3. NCT02061449

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

Cutaneous T-cell Lymphoma Clinical Trial

Official title:
A Pilot Study of a Novel Multimodality Immuno-Chemotherapy Platform for Patients With Advanced Cutaneous T Cell Lymphoma

Clinical Trial Summary

This study evaluates the safety and tolerability of the addition of immunostimulatory therapy consisting of focal radiation with or without the Toll-like receptor (TLR) agonist Poly ICLC in patients with cutaneous T-cell lymphoma (CTCL) receiving concurrent therapy with the histone deacetylase inhibitor (HDACI) Romidepsin.

Clinical Trial Description

Histone deacetylase inhibitors in epigenetic therapy are one of the most active anti-tumor agents in patients with relapsed and refractory CTCL despite their suppressive effects on T cell function, yet the overall response rate and response duration with these agents remains suboptimal. Immune stimulatory agents may be the ideal therapy to combine with HDACI. To date, no one has evaluated whether the abscopal effect of radiation with and without the additional immune stimulation of a TLR-3 agonist can augmented the efficacy of anti-tumor directed epigenetic therapy in mycosis fungoides (MF) patients. The investigators hypothesize that a combined modality immuno-chemotherapy may be highly effective in patients with advanced MF.

This is a phase I study. It involves two arms of patients (A and B) who will be treated following a standard 3+ 3 design. Patients on Arm A are the ones who are initiating HDACI therapy, and patients on Arm B are the ones with stable disease or partial response with HDACI treatment. Both groups receive HDACI, plus at level 1, focal lesional radiation; at level 2, radiation in combination with Poly ICLC. Each arm will be evaluated and escalated independently. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02061449
Study type Interventional
Source New York University School of Medicine
Contact
Status Terminated
Phase Phase 1
Start date March 2014
Completion date November 5, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT00038025 - A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Phase 2
Not yet recruiting NCT02881749 - Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides Phase 2
Completed NCT00744991 - A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma Phase 2
Completed NCT00099593 - Immunization Against Tumor Cells in Sezary Syndrome Phase 2
Completed NCT02593045 - Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) Phase 1
Recruiting NCT00779896 - Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study Phase 1/Phase 2
Recruiting NCT00177268 - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Completed NCT01728805 - Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Phase 3
Withdrawn NCT00969085 - Trial of Curcumin in Cutaneous T-cell Lymphoma Patients Phase 2
Completed NCT00412997 - LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma Phase 1
Completed NCT00254332 - Effect of Denileukin Diftitox on Immune System in CTCL Patients N/A
Recruiting NCT04296786 - Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study Phase 2
Recruiting NCT06285370 - A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy Phase 4
Completed NCT00071084 - Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. Phase 2
Completed NCT00896493 - Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Phase 2
Terminated NCT00699296 - Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma Phase 2
Completed NCT02676778 - Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma Phase 2
Completed NCT01134341 - Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT05296304 - A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides Phase 1